Pfizer ROE 2006-2018 | PFE

Current and historical return on equity (ROE) values for Pfizer (PFE) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Pfizer ROE for the three months ending June 30, 2018 was 25.35%.
Pfizer ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-06-30 $22.55B $70.12B 32.98%
2018-03-31 $21.75B $70.54B 33.20%
2017-12-31 $21.31B $71.66B 34.06%
2017-09-30 $9.81B $61.11B 16.46%
2017-06-30 $8.32B $58.69B 13.82%
2017-03-31 $7.30B $58.75B 11.90%
2016-12-31 $7.22B $59.84B 11.55%
2016-09-30 $6.27B $63.60B 9.83%
2016-06-30 $7.04B $63.07B 10.90%
2016-03-31 $7.62B $63.35B 11.61%
2015-12-31 $6.96B $65.00B 10.43%
2015-09-30 $8.36B $67.12B 12.23%
2015-06-30 $8.90B $67.18B 12.50%
2015-03-31 $9.18B $67.59B 12.47%
2014-12-31 $9.14B $71.62B 11.98%
2014-09-30 $10.48B $78.31B 13.52%
2014-06-30 $10.40B $76.96B 13.42%
2014-03-31 $21.58B $78.07B 27.67%
2013-12-31 $22.00B $76.62B 27.78%
2013-09-30 $25.75B $78.35B 32.00%
2013-06-30 $26.37B $78.98B 32.39%
2013-03-31 $15.53B $82.83B 19.02%
2012-12-31 $14.57B $81.68B 17.80%
2012-09-30 $9.69B $82.12B 11.81%
2012-06-30 $10.22B $79.96B 12.14%
2012-03-31 $9.58B $83.68B 11.08%
2011-12-31 $10.01B $82.62B 11.35%
2011-09-30 $11.46B $90.53B 12.79%
2011-06-30 $8.59B $88.96B 9.65%
2011-03-31 $8.45B $90.53B 9.56%
2010-12-31 $8.26B $88.27B 9.35%
2010-09-30 $6.13B $88.07B 6.90%
2010-06-30 $8.15B $86.88B 9.77%
2010-03-31 $7.93B $90.08B 10.23%
2009-12-31 $8.64B $90.45B 12.32%
2009-09-30 $8.13B $66.25B 13.14%
2009-06-30 $7.53B $63.24B 12.11%
2009-03-31 $8.05B $60.44B 12.77%
2008-12-31 $8.10B $57.74B 12.51%
2008-09-30 $10.56B $67.34B 15.86%
2008-06-30 $9.05B $66.57B 13.62%
2008-03-31 $7.54B $67.42B 11.28%
2007-12-31 $8.14B $65.01B 11.97%
2007-09-30 $14.87B $66.61B 21.35%
2007-06-30 $17.47B $68.09B 24.81%
2007-03-31 $18.62B $72.49B 26.40%
2006-12-31 $19.34B $71.36B 27.71%
2006-09-30 $12.62B $69.71B 18.45%
2006-06-30 $10.85B $68.49B 16.03%
2006-03-31 $11.90B $69.61B 17.79%
2005-12-31 $8.09B $65.76B 12.18%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $264.902B $52.546B
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $373.058B 17.49
Novartis AG (NVS) Switzerland $202.059B 17.26
Merck (MRK) United States $195.069B 17.23
AbbVie (ABBV) United States $133.211B 13.01
Eli Lilly (LLY) United States $120.201B 22.25
Sanofi (SNY) France $111.785B 14.15
Novo Nordisk (NVO) Denmark $105.487B 16.86
GlaxoSmithKline (GSK) United Kingdom $101.355B 13.53
AstraZeneca (AZN) United Kingdom $99.315B 10.92
Bristol-Myers Squibb (BMY) United States $88.755B 16.07